Neurocrine launches PWS-VISTA real-world study tracking VYKAT XR use in Prader-Willi syndrome

• Neurocrine flagged new real-world studies on VYKAT XR use in Prader-Willi syndrome ahead of an FPWR conference in October.
• Findings will be presented in the future, including baseline patient profiles from PWS-VISTA, a longitudinal observational study in routine care.
• A separate BRAVE-PWS study will track caregiver-reported burden to sharpen understanding of day-to-day disease impact.
• Additional analyses will assess key safety risks during VYKAT XR treatment, aiming to strengthen the product’s benefit-risk profile.
• VYKAT XR is positioned as the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome for patients aged 4 or older.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609300830PR_NEWS_USPR_____LA59565) on September 30, 2026, and is solely responsible for the information contained therein.